Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714

R. Haddad, M. Gillison, R. L. Ferris, K. Harrington, M. Monga, C. Baudelet, W. J. Geese, A. Argiris

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)vi350
JournalAnnals of Oncology
StatePublished - Oct 1 2016
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this